Ken Griffin
KAPA

Ken Griffin’s Kairos Pharma KAPA Stock Holding History

Ken Griffin’s Portfolio KAPA Stock Details KAPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-321,738
Closed -$228K – 14539
2025
Q4 		$228K Buy
+321,738
New +$301K ﹤0.01% 10748
2025
Q2 		– Sell
-13,230
Closed -$12.4K – 15613
2025
Q1 		$12.4K Buy
13,230
+2,261
+21% +$2.9K ﹤0.01% 13450
2024
Q4 		$16.7K Buy
+10,969
New +$16.8K ﹤0.01% 13291

Other funds holding KAPA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
SFG
SevenBridge Financial Group Harrisburg, Pennsylvania $680M AUM 30.75% 1-Year Est. Return
ACA
Aptus Capital Advisors Fairhope, Alabama $12.7B AUM 17.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Ken Griffin's KAPA Position: Q1 2026 in Review

Ken Griffin sold out of Kairos Pharma (KAPA) in Q1 2026, closing a stake of 321,738 shares — an estimated $228K sold.

Ken Griffin first reported a position in KAPA in Q4 2024 and held it in 3 quarters. The position peaked at $228K in Q4 2025. 11 funds tracked by Wall St. Rank hold KAPA as of Q1 2026.

  • Ken Griffin reported no remaining Kairos Pharma position as of Q1 2026 after selling out during the quarter.
  • Ken Griffin sold 321,738 Kairos Pharma shares in Q1 2026, an estimated $228K.
  • Ken Griffin first reported a position in Kairos Pharma in Q4 2024 and held it in 3 quarters.
  • Ken Griffin's Kairos Pharma position peaked at $228K in Q4 2025.
  • 11 funds tracked by Wall St. Rank held Kairos Pharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.